Since the inception of radionuclide therapies by John Lawrence and Saul Hertz over 80 y ago, little has changed regarding ...
Radiopharmaceuticals have emerged as a transformative modality in precision oncology, with growing potential in non-oncologic ...
Radiopharmaceutical therapy (RPT) delivers protracted, low absorbed dose rate radiation over time, with cellular DNA repair ...
The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the ...
Journal of Nuclear Medicine July 2026, jnumed.125.271916; DOI: https://doi.org/10.2967/jnumed.125.271916 ...
WHY IS FAP-TARGETED THERAPY ATTRACTIVE? FAP-positive CAFs are found in more than 90% of epithelial cancers, therefore representing a potential pan-cancer target (6). Targeting FAP to deplete stromal ...
TO THE EDITOR: We read with great interest the recent publication entitled “Dr. Li Wenliang and the Time of COVID-19” (1). As mentioned in this article, Dr. Li was reprimanded initially for ...
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA) ...
Journal of Nuclear Medicine June 2025, 66 (supplement 1) 252173; ...
The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a ...
Journal of Nuclear Medicine January 2026, jnumed.125.271317; DOI: https://doi.org/10.2967/jnumed.125.271317 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results